follow us in feedly
AKTX stock

Akari Therapeutics (NASDAQ:AKTX) is making headlines after the biopharmaceutical company announced positive data from a Phase 2 clinical trial. The news, released today, sent AKTX stock up nearly 20% at the time of writing.

Read

MOST RECENT ARTICLES

1 2 3 4 140

Welcome

MicroSmallCap offers you up-to-date, high quality news and information on the small cap companies that matter. Stay informed on current investing news and trends across the markets.

Advertise with MicroSmallCap
Write for MicroSmallCap
Submit your Company News

INVESTOR NEWS